OncoMatch/Clinical Trials/NCT06537843
Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia
Is NCT06537843 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Venetoclax and Cytarabine for acute myeloid leukemia.
Treatment: Venetoclax · Cytarabine · Metformin — Phase 2 clinical trial to evaluate the combination of venetoclax, cytarabine and metformin in relapsed-refractory and induction ineligible acute myeloid leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 2–3(Limited self-care)
Lab requirements
Kidney function
creatinine clearance below 60 mL/min/1,73m²
Cardiac function
left ventricular ejection fraction ≤ 50%
creatinine clearance below 60 mL/min/1,73m², left ventricular ejection fraction ≤ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06537843 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages